West Pharmaceutical Services Stock Issuance Proceeds increased by 77.4% to $5.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 120.0%, from $2.50M to $5.50M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -21.3% CAGR.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.00M | $5.30M | $6.30M | $6.30M | $4.40M | $6.40M | $3.80M | $13.50M | $10.50M | $18.60M | $1.30M | $14.80M | $5.10M | $4.10M | $1.50M | $2.50M | $3.50M | $2.20M | $3.10M | $5.50M |
| QoQ Change | — | -55.8% | +18.9% | +0.0% | -30.2% | +45.5% | -40.6% | +255.3% | -22.2% | +77.1% | -93.0% | >999% | -65.5% | -19.6% | -63.4% | +66.7% | +40.0% | -37.1% | +40.9% | +77.4% |
| YoY Change | — | — | — | — | -63.3% | +20.8% | -39.7% | +114.3% | +138.6% | +190.6% | -65.8% | +9.6% | -51.4% | -78.0% | +15.4% | -83.1% | -31.4% | -46.3% | +106.7% | +120.0% |